Skip to main content

Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis.

Publication ,  Journal Article
Al Hroot, J; Reeder, J; Yuan, X; Gu, K; Walter, EB; Boole, L; Que, LG; An, G
Published in: Antimicrob Agents Chemother
June 4, 2025

Fosfomycin, a broad-spectrum antibiotic used for uncomplicated cystitis, represents a potential promising candidate in combating resistant pneumonia. To facilitate the transition of fosfomycin to broader indications, including pneumonia, a minimal physiologically based pharmacokinetics (m-PBPK) model for fosfomycin was developed based on data from plasma, epithelial lining fluid (ELF), and alveolar macrophages (AMs) obtained from 37 healthy participants in a recently completed intrapulmonary PK study. Utilizing this mechanistic m-PBPK model enabled us to predict drug concentrations at the infection site in pneumonia patients, taking into consideration the pathophysiological changes occurring during the infection. Our prediction shows that the drug concentrations at the infection site reduced, while plasma levels remain unchanged. Monte Carlo simulations were conducted to evaluate the probability of target attainment (PTA) for various dosing regimens infused over 1 h against major hospital-acquired pneumonia pathogens in plasma and ELF. Our PTA analysis suggested that if plasma concentrations are the appropriate efficacy indicator, a dose of 4 g q8h is sufficient for Pseudomonas aeruginosa and Staphylococcus aureus infections. However, if ELF concentrations are a more accurate indicator, this dose is only effective for S. aureus pneumonia. For P. aeruginosa pneumonia, a dose of 6 g q8h is recommended, with an even higher dose of 8 g q8h necessary for pneumonia patients. In conclusion, our model provides critical insights into fosfomycin dosing for pneumonia treatment, guiding clinical study design. Furthermore, it serves as a platform to evaluate intrapulmonary pharmacokinetics for other antibiotics.

Duke Scholars

Published In

Antimicrob Agents Chemother

DOI

EISSN

1098-6596

Publication Date

June 4, 2025

Volume

69

Issue

6

Start / End Page

e0186924

Location

United States

Related Subject Headings

  • Staphylococcus aureus
  • Pseudomonas aeruginosa
  • Pseudomonas Infections
  • Pneumonia, Bacterial
  • Pneumonia
  • Monte Carlo Method
  • Models, Biological
  • Middle Aged
  • Microbiology
  • Microbial Sensitivity Tests
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Al Hroot, J., Reeder, J., Yuan, X., Gu, K., Walter, E. B., Boole, L., … An, G. (2025). Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis. Antimicrob Agents Chemother, 69(6), e0186924. https://doi.org/10.1128/aac.01869-24
Al Hroot, Jomana, Joshua Reeder, Xuanzhen Yuan, Kenan Gu, Emmanuel B. Walter, Lindsay Boole, Loretta G. Que, and Guohua An. “Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis.Antimicrob Agents Chemother 69, no. 6 (June 4, 2025): e0186924. https://doi.org/10.1128/aac.01869-24.
Al Hroot J, Reeder J, Yuan X, Gu K, Walter EB, Boole L, et al. Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis. Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0186924.
Al Hroot, Jomana, et al. “Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis.Antimicrob Agents Chemother, vol. 69, no. 6, June 2025, p. e0186924. Pubmed, doi:10.1128/aac.01869-24.
Al Hroot J, Reeder J, Yuan X, Gu K, Walter EB, Boole L, Que LG, An G. Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis. Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0186924.

Published In

Antimicrob Agents Chemother

DOI

EISSN

1098-6596

Publication Date

June 4, 2025

Volume

69

Issue

6

Start / End Page

e0186924

Location

United States

Related Subject Headings

  • Staphylococcus aureus
  • Pseudomonas aeruginosa
  • Pseudomonas Infections
  • Pneumonia, Bacterial
  • Pneumonia
  • Monte Carlo Method
  • Models, Biological
  • Middle Aged
  • Microbiology
  • Microbial Sensitivity Tests